| | | | | |
Unadjusted
|
Adjusted
b
|
|---|
|
First replication
|
G1m genotype
a
|
number
|
Baseline DAS28
|
ΔDAS28
|
Beta
|
P-value
|
Beta
|
P-value
|
|---|
|
All patients
|
G1m1,17+
|
228
|
6.4 ± 1.1
|
2.5 ± 1.3
|
0.03
|
0.52
|
0.07
|
0.13
|
|
G1m1,17-
|
176
|
6.6 ± 1.1
|
2.4 ± 1.3
| | | | |
|
INX
|
G1m1,17+
|
116
|
6.7 ± 0.9
|
2.5 ± 1.2
|
0.14
|
0.04
|
0.15
|
0.02
|
|
G1m1,17-
|
83
|
6.8 ± 1.1
|
2.2 ± 1.3
| | | | |
|
ADM
|
G1m1,17+
|
112
|
6.1 ± 1.1
|
2.4 ± 1.3
|
−0.07
|
0.32
|
−0.01
|
0.83
|
|
G1m1,17-
|
93
|
6.4 ± 1.0
|
2.8 ± 1.3
| | | | |
|
Second replication
| | | | | | | | |
|
INX
|
G1m1,17+
|
203
|
6.2 ± 1.1
|
2.2 ± 1.5
|
0.11
|
0.03
|
0.08
|
0.08
|
|
G1m1,17-
|
159
|
6.1 ± 1.3
|
1.9 ± 1.5
| | | | |
-
aCarrier status; banalyses adjusted for baseline DAS28 and gender (and anti-TNF for All patients). ADM, adalimumab; DAS28, disease activity score in 28 joints; IFX, infliximab.
